{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:38:17Z","timestamp":1790811497895,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Region Ile de France ARDoc"},{"name":"CAM"},{"name":"Instituto de Salud Carlos III-FEDER","award":["PI18\/01875"],"award-info":[{"award-number":["PI18\/01875"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neutrophil gelatinase-associated lipocalin (NGAL) is involved in cardiovascular and renal diseases. Gene inactivation of NGAL blunts the pathophysiological consequences of cardiovascular and renal damage. We aimed to design chemical NGAL inhibitors and investigate its effects in experimental models of myocardial infarction (MI) and chronic kidney disease induced by 5\/6 nephrectomy (CKD) on respectively 8\u201312\u00a0weeks old C57Bl6\/j and FVB\/N male mice. Among the 32 NGAL inhibitors tested, GPZ614741 and GPZ058225 fully blocked NGAL-induced inflammatory and profibrotic markers in human cardiac fibroblasts and primary mouse kidney fibroblasts. The administration of GPZ614741 (100\u00a0mg\/kg\/day) for three months, was able to improve cardiac function in MI mice and reduced myocardial fibrosis and inflammation. The administration of GPZ614741 (100\u00a0mg\/kg\/day) for two months resulting to no renal function improvement but prevented the increase in blood pressure, renal tubulointerstitial fibrosis and profibrotic marker expression in CKD mice. In conclusion, we have identified new compounds with potent inhibitory activity on NGAL-profibrotic and pro-inflammatory effects. GPZ614741 prevented interstitial fibrosis and dysfunction associated with MI, as well as tubulointerstitial fibrosis in a CKD model. These inhibitors could be used for other diseases that involve NGAL, such as cancer or metabolic diseases, creating new therapeutic options.<\/jats:p>","DOI":"10.1038\/s41598-021-82279-0","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T11:04:39Z","timestamp":1611831879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models"],"prefix":"10.1038","volume":"11","author":[{"given":"Benjamin","family":"Bonnard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Mart\u00ednez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaya","family":"Fern\u00e1ndez-Celis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Pieronne-Deperrois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quoc-Tuan","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isbaal","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Ouvrard-Pascaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"L\u00f3pez-Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"key":"82279_CR1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/bcpt.13332","volume":"127","author":"D Li","year":"2019","unstructured":"Li, D., Yan Sun, W., Fu, B., Xu, A. & Wang, Y. Lipocalin-2-The myth of its expression and function. Basic Clin. Pharmacol. Toxicol. 127, 142\u2013151 (2019).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"82279_CR2","first-page":"5017","volume":"14","author":"J Zhang","year":"2017","unstructured":"Zhang, J. et al. Clinical significance of novel biomarker NGAL in early diagnosis of acute renal injury. Exp. Ther. Med. 14, 5017\u20135021 (2017).","journal-title":"Exp. Ther. Med."},{"key":"82279_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13613-020-00667-7","volume":"10","author":"S Tornblom","year":"2020","unstructured":"Tornblom, S. et al. Urine NGAL as a biomarker for septic AKI: A critical appraisal of clinical utility-data from the observational FINNAKI study. Ann. Intensive Care. 10, 51 (2020).","journal-title":"Ann. Intensive Care."},{"key":"82279_CR4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nchembio.402","volume":"6","author":"G Bao","year":"2010","unstructured":"Bao, G. et al. Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat. Chem. Biol. 6, 602\u2013609 (2010).","journal-title":"Nat. Chem. Biol."},{"key":"82279_CR5","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/eji.201142351","volume":"42","author":"A Schroll","year":"2012","unstructured":"Schroll, A. et al. Lipocalin-2 ameliorates granulocyte functionality. Eur. J. Immunol. 42, 3346\u20133357 (2012).","journal-title":"Eur. J. Immunol."},{"key":"82279_CR6","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jid.2016.03.002","volume":"136","author":"S Shao","year":"2016","unstructured":"Shao, S. et al. Increased lipocalin-2 contributes to the pathogenesis of psoriasis by modulating neutrophil chemotaxis and cytokine secretion. J. Invest. Dermatol. 136, 1418\u20131428 (2016).","journal-title":"J. Invest. Dermatol."},{"key":"82279_CR7","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S1097-2765(02)00708-6","volume":"10","author":"DH Goetz","year":"2002","unstructured":"Goetz, D. H. et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell. 10, 1033\u20131043 (2002).","journal-title":"Mol. Cell."},{"key":"82279_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3892\/ijo.2015.3245","volume":"48","author":"RK Mongre","year":"2016","unstructured":"Mongre, R. K. et al. Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-kappaB inhibitor BRM270 in a xenograft model of lung adenocarcinoma. Int. J. Oncol. 48, 84\u201398 (2016).","journal-title":"Int. J. Oncol."},{"key":"82279_CR9","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1073\/pnas.0810617106","volume":"106","author":"J Yang","year":"2009","unstructured":"Yang, J. et al. Lipocalin 2 promotes breast cancer progression. Proc. Natl. Acad. Sci. USA. 106, 3913\u20133918 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"82279_CR10","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1056\/NEJMra1916393","volume":"382","author":"M Legrand","year":"2020","unstructured":"Legrand, M. & Rossignol, P. Cardiovascular consequences of acute kidney injury. N. Engl. J. Med. 382, 2238\u20132247 (2020).","journal-title":"N. Engl. J. Med."},{"key":"82279_CR11","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.117.09791","volume":"70","author":"E Martinez-Martinez","year":"2017","unstructured":"Martinez-Martinez, E. et al. Aldosterone target NGAL (neutrophil gelatinase-associated lipocalin) is involved in cardiac remodeling after myocardial infarction through NFkappaB pathway. Hypertension 70, 1148\u20131156 (2017).","journal-title":"Hypertension"},{"key":"82279_CR12","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/jcp.25672","volume":"232","author":"HK Sung","year":"2017","unstructured":"Sung, H. K. et al. Lipocalin-2 (NGAL) attenuates autophagy to exacerbate cardiac apoptosis induced by myocardial ischemia. J. Cell Physiol. 232, 2125\u20132134 (2017).","journal-title":"J. Cell Physiol."},{"key":"82279_CR13","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1172\/JCI42004","volume":"120","author":"A Viau","year":"2010","unstructured":"Viau, A. et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J. Clin. Invest. 120, 4065\u20134076 (2010).","journal-title":"J. Clin. Invest."},{"key":"82279_CR14","doi-asserted-by":"publisher","first-page":"e000837","DOI":"10.1161\/JAHA.114.000837","volume":"3","author":"E Song","year":"2014","unstructured":"Song, E. et al. Deamidated lipocalin-2 induces endothelial dysfunction and hypertension in dietary obese mice. J. Am. Heart Assoc. 3, e000837 (2014).","journal-title":"J. Am. Heart Assoc."},{"key":"82279_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/minf.201700023","author":"JM Gally","year":"2010","unstructured":"Gally, J. M., Bourg, S., Do, Q. T., Aci-Seche, S. & Bonnet, P. VSPrep: A general KNIME workflow for the preparation of molecules for virtual screening. Mol. Inform. (2017). https:\/\/doi.org\/10.1002\/minf.201700023.","journal-title":"Mol. Inform."},{"key":"82279_CR16","doi-asserted-by":"publisher","first-page":"W407","DOI":"10.1093\/nar\/gkq502","volume":"38","author":"LM Meireles","year":"2010","unstructured":"Meireles, L. M., Domling, A. S. & Camacho, C. J. ANCHOR: A web server and database for analysis of protein-protein interaction binding pockets for drug discovery. Nucleic Acids Res. 38, W407-411 (2010).","journal-title":"Nucleic Acids Res."},{"key":"82279_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10822-007-9114-2","volume":"21","author":"AN Jain","year":"2007","unstructured":"Jain, A. N. Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J. Comput. Aided Mol. Des. 21, 281\u2013306 (2007).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"82279_CR18","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00018-019-03423-8","volume":"77","author":"S Ghosh","year":"2020","unstructured":"Ghosh, S. et al. The role of lipocalin-2 in age-related macular degeneration (AMD). Cell Mol. Life Sci. 77, 835\u2013851 (2020).","journal-title":"Cell Mol. Life Sci."},{"key":"82279_CR19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1042\/CS20171592","volume":"132","author":"M Buonafine","year":"2018","unstructured":"Buonafine, M., Martinez-Martinez, E. & Jaisser, F. More than a simple biomarker: The role of NGAL in cardiovascular and renal diseases. Clin. Sci. (Lond.). 132, 909\u2013923 (2018).","journal-title":"Clin. Sci. (Lond.)."},{"key":"82279_CR20","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1080\/0886022X.2016.1227917","volume":"38","author":"Q Ma","year":"2016","unstructured":"Ma, Q., Devarajan, S. R. & Devarajan, P. Amelioration of cisplatin-induced acute kidney injury by recombinant neutrophil gelatinase-associated lipocalin. Ren. Fail. 38, 1476\u20131482 (2016).","journal-title":"Ren. Fail."},{"key":"82279_CR21","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/ki.2012.195","volume":"82","author":"TL Nickolas","year":"2012","unstructured":"Nickolas, T. L. et al. NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease. Kidney Int. 82, 718\u2013722 (2012).","journal-title":"Kidney Int."},{"key":"82279_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.molmet.2019.03.007","volume":"24","author":"JA Deis","year":"2019","unstructured":"Deis, J. A. et al. Adipose Lipocalin 2 overexpression protects against age-related decline in thermogenic function of adipose tissue and metabolic deterioration. Mol. Metab. 24, 18\u201329 (2019).","journal-title":"Mol. Metab."},{"key":"82279_CR23","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1158\/0008-5472.CAN-09-1934","volume":"69","author":"X Leng","year":"2009","unstructured":"Leng, X. et al. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 69, 8579\u20138584 (2009).","journal-title":"Cancer Res."},{"key":"82279_CR24","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI67911","volume":"123","author":"JM Warszawska","year":"2013","unstructured":"Warszawska, J. M. et al. Lipocalin 2 deactivates macrophages and worsens pneumococcal pneumonia outcomes. J. Clin. Invest. 123, 3363\u20133372 (2013).","journal-title":"J. Clin. Invest."},{"key":"82279_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/sji.12245","volume":"81","author":"L Cheng","year":"2015","unstructured":"Cheng, L. et al. Lipocalin-2 promotes m1 macrophages polarization in a mouse cardiac ischaemia-reperfusion injury model. Scand J Immunol. 81, 31\u201338 (2015).","journal-title":"Scand J Immunol."},{"key":"82279_CR26","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jhep.2015.11.037","volume":"64","author":"V Wieser","year":"2016","unstructured":"Wieser, V. et al. Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease. J. Hepatol. 64, 872\u2013880 (2016).","journal-title":"J. Hepatol."},{"key":"82279_CR27","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3389\/fimmu.2019.00746","volume":"10","author":"S Shao","year":"2019","unstructured":"Shao, S. et al. Neutrophil Extracellular Traps Promote Inflammatory Responses in Psoriasis via Activating Epidermal TLR4\/IL-36R Crosstalk. Front Immunol. 10, 746 (2019).","journal-title":"Front Immunol."},{"key":"82279_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1160\/TH06-11-0638","volume":"98","author":"M Folkesson","year":"2007","unstructured":"Folkesson, M. et al. Presence of NGAL\/MMP-9 complexes in human abdominal aortic aneurysms. Thromb. Haemost. 98, 427\u2013433 (2007).","journal-title":"Thromb. Haemost."},{"key":"82279_CR29","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.atherosclerosis.2011.11.023","volume":"220","author":"P Ramos-Mozo","year":"2012","unstructured":"Ramos-Mozo, P. et al. Increased plasma levels of NGAL, a marker of neutrophil activation, in patients with abdominal aortic aneurysm. Atherosclerosis. 220, 552\u2013556 (2012).","journal-title":"Atherosclerosis."},{"key":"82279_CR30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/cvr\/cvw112","volume":"111","author":"C Tarin","year":"2016","unstructured":"Tarin, C. et al. Lipocalin-2 deficiency or blockade protects against aortic abdominal aneurysm development in mice. Cardiovasc. Res. 111, 262\u2013273 (2016).","journal-title":"Cardiovasc. Res."},{"key":"82279_CR31","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.dib.2016.06.047","volume":"8","author":"P Saha","year":"2016","unstructured":"Saha, P., Singh, V., Xiao, X., Yeoh, B. S. & Vijay-Kumar, M. Data on importance of hematopoietic cell derived Lipocalin 2 against gut inflammation. Data Brief. 8, 812\u2013816 (2016).","journal-title":"Data Brief."},{"key":"82279_CR32","first-page":"105","volume":"10","author":"X Duan","year":"2018","unstructured":"Duan, X. et al. Tumor associated macrophages deliver iron to tumor cells via Lcn2. Int. J. Physiol. Pathophysiol. Pharmacol. 10, 105\u2013114 (2018).","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"key":"82279_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/path.4724","volume":"239","author":"B Oren","year":"2016","unstructured":"Oren, B. et al. Tumour stroma-derived lipocalin-2 promotes breast cancer metastasis. J. Pathol. 239, 274\u2013285 (2016).","journal-title":"J. Pathol."},{"key":"82279_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/thno.12167","volume":"6","author":"P Guo","year":"2016","unstructured":"Guo, P., Yang, J., Jia, D., Moses, M. A. & Auguste, D. T. ICAM-1-targeted, Lcn2 siRNA-encapsulating liposomes are potent anti-angiogenic agents for triple negative breast cancer. Theranostics. 6, 1\u201313 (2016).","journal-title":"Theranostics."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82279-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82279-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82279-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:53:56Z","timestamp":1670036036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82279-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82279"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82279-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,28]]},"assertion":[{"value":"2 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Mart\u00ednez-Mart\u00ednez, Dr. Mulder, Dr. Do, Dr. Ouvrard-Pascaud, Dr. L\u00f3pez-Andr\u00e9s and Dr. Jaisser have filed a patent on the use of NGAL inhibitors. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2591"}}